Comparative Tolerability of Drug Therapies for Hypercalcaemia of Malignancy
- 1 January 1999
- journal article
- research article
- Published by Springer Science and Business Media LLC in Drug Safety
- Vol. 21 (5), 389-406
- https://doi.org/10.2165/00002018-199921050-00004
Abstract
No abstract availableKeywords
This publication has 98 references indexed in Scilit:
- Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injectionJournal of Bone and Mineral Research, 1996
- Adverse Effects of BisphosphonatesDrug Safety, 1996
- Infusion rate and pharmacokinetics of intravenous pamidronate in the treatment of tumour-induced hypercalcaemiaPublished by Oxford University Press (OUP) ,1992
- Intravenous clodronate for the treatment of hypercalcaemia in breast cancer patients with bone metastases—A prospective randomised placebo-controlled multicentre studyEuropean Journal Of Cancer, 1992
- Disodium Pamidronate Versus Mithramycin in the Management of Tumour-Associated HypercalcemiaActa Oncologica, 1992
- BisphosphonatesDrugs, 1991
- Severe hypocalcaemia [corrected] after treatment with diphosphonate and aminoglycoside.BMJ, 1991
- Monotherapie mit Clodronat bei tumorinduzierter HypercalcämieDeutsche Medizinische Wochenschrift (1946), 1990
- Nephrotoxicity following Single Dose Mithramycin TherapyAmerican Journal of Nephrology, 1983
- Doxycycline for Travelers' Diarrhea: Risks and BenefitsNew England Journal of Medicine, 1978